ABOUT DIAMYD MEDICAL
ABOUT DIAMYD MEDICAL
CEO Comments
The Diamyd Story
Board & Management
Contact Us
Corporate Governance
Annual General Meeting
Auditors
Incentive Programs
Articles of Association
Diamyd US Operations
Partnering
DIABETES
DIABETES
Type 1
LADA
Type 2
Complications
Diamyd
®
Products
PRODUCTS & PIPELINE
PRODUCTS & PIPELINE
Diamyd
®
Products
Diamyd
®
for type 1
Diamyd
®
for LADA
NTDDS products
NP2
NG2
NC3
Partnering
SCIENCE & TECHNOLOGY
SCIENCE & TECHNOLOGY
GAD platform
NTDDS platform
Clinical development
Scientific publications
Scientific advisory board
Order GAD for research
CLINICAL TRIALS
CLINICAL TRIALS
Phase III Trials - USA
Phase III Trials - Europe
INVESTOR RELATIONS
INVESTOR RELATIONS
Share Issue
Extraordinary General Meeting
Press Releases
Financial Reports
IR Calendar
Owners
Share Trading
Board & Management
Corporate Governance
Annual General Meeting
Auditors
Incentive Programs
Articles of Association
PRESS ROOM
PRESS ROOM
Press Releases
News & Mediawatch
Webcasts/Podcasts
Newsletter Subscription
Media Contact
Home
»
Clinical Trials
»
Phase III Studies - Europe
Clinical Trials - Studies in Europe
Diamyd Medical is currently conducting two clinical Phase III studies on type 1 diabetes: one in Europe and one in the United States. These studies apply to people diagnosed with type 1 diabetes within the past three months. The participating countries in Europe are Sweden, the Netherlands, Finland, France, Germany, Italy, the UK, Slovenia and Spain.
Finland
France
Germany
Italy
Netherlands
Slovenia
Spain
Sweden
United Kingdom
Clinical Trials
Phase III Trials - USA
Phase III Trials - Europe
Related links
European Phase III study with Diamyd
®